Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALICE: Durvalumab and Tremelimumab +/- HAIC with GEMOX in HCC
NCT06904170Phase 3Recruiting
- Sponsor
- Unicancer
- Start
- Nov 2025
- Primary completion
- Sep 2029
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 3 trial of gemcitabine, oxaliplatin in hepatocellular carcinoma (HCC), sponsored by Unicancer. Started Nov 2025; status: recruiting.
02
Drugs
gemcitabineoxaliplatin
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT06904170.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06904170.